AstraZeneca faces pivotal test as spotlight shifts to Baxdrostat's 24-hour data

Market attention on AstraZeneca's experimental blood pressure drug, Baxdrostat, has shifted to its imminent BAX24 readout, which will assess 24-hour ambulatory blood pressure control—a key metric for physicians despite promising initial office-based data. Deutsche Bank maintains a 'hold' rating, expressing skepticism that BAX24 will demonstrate sufficient differentiation from rivals like lorundrostat to ensure commercial viability, particularly given payer resistance to new, expensive treatments over generics. The results are pivotal for determining Baxdrostat's market potential.

Analysis

Market focus on AstraZeneca's experimental blood pressure treatment, Baxdrostat, has pivoted from its initially promising Phase III office-based data to the imminent results of the BAX24 study. This shift is critical as a recent physician poll, highlighted by Deutsche Bank, revealed a "surprising emphasis" on 24-hour ambulatory blood pressure monitoring, which BAX24 is designed to assess and is considered more indicative of real-world efficacy and long-term cardiovascular risk. Despite the initial positive findings in patients with resistant hypertension, Deutsche Bank maintains a cautious 'hold' rating and expresses skepticism that the BAX24 results will provide clear differentiation from a key competitor, lorundrostat. This competitive pressure is compounded by potential resistance from payors who may question the value of a new, expensive agent over cheap generics. The upcoming data is therefore a pivotal catalyst that will largely determine Baxdrostat's commercial viability, a sentiment reflected in the stock's 1% decline to 11,960p, which remains above Deutsche Bank's 11,000p target price.

Key Decisions for Investors

• Investors should treat the imminent BAX24 trial results as a significant binary event for AstraZeneca, with the outcome likely to be a primary driver of near-term stock performance.
• It is critical to evaluate the BAX24 data not just on efficacy but on its differentiation from rival drug lorundrostat, as this will be key to securing market access and convincing payors.
• Given the cautious analyst sentiment and the stock trading above Deutsche Bank's price target, investors may consider hedging or trimming positions to mitigate downside risk ahead of the potentially volatile data release.